2026-06-14T03:54:09Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/143902025-04-07T13:43:05Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16958col_20.500.12105_16962col_20.500.12105_16963col_20.500.12105_16978

00925njm 22002777a 4500 dc Salto-Alejandre, Sonsoles author Palacios-Baena, Zaira R author Arribas, José Ramón author Berenguer, Juan author Carratalà, Jordi author Jarrin Vera, Inmaculada author Ryan, Pablo author Miguel-Montero, Marta de author Rodríguez-Baño, Jesús author Pachón, Jerónimo author COVID-19@Spain Study Group author 2022-02 Background: Interferon-β is an attractive drug for repurposing and use in the treatment of COVID-19, based on its in vitro antiviral activity and the encouraging results from clinical trials. The aim of this study was to analyze the impact of early interferon-β treatment in patients admitted with COVID-19 during the first wave of the pandemic. Methods: This post hoc analysis of a COVID-19@Spain multicenter cohort included 3808 consecutive adult patients hospitalized with COVID-19 from 1 January to 17 March 2020. The primary endpoint was 30-day all-cause mortality, and the main exposure of interest was subcutaneous administration of interferon-β, defined as early if started ≤ 3 days from admission. Multivariate logistic and Cox regression analyses were conducted to identify the associations of different variables with receiving early interferon-β therapy and to assess its impact on 30-day mortality. A propensity score was calculated and used to both control for confounders and perform a matched cohort analysis. Results: Overall, 683 patients (17.9%) received early interferon-β therapy. These patients were more severely ill. Adjusted HR for mortality with early interferon-β was 1.03 (95% CI, 0.82-1.30) in the overall cohort, 0.96 (0.82-1.13) in the PS-matched subcohort, and 0.89 (0.60-1.32) when interferon-β treatment was analyzed as a time-dependent variable. Conclusions: In this multicenter cohort of admitted COVID-19 patients, receiving early interferon-β therapy after hospital admission did not show an association with lower mortality. Whether interferon-β might be useful in the earlier stages of the disease or specific subgroups of patients requires further research. Biomed Pharmacother. 2022 Feb;146:112572. 10.1016/j.biopha.2021.112572 1950-6007 Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 34954640 http://hdl.handle.net/20.500.12105/14390 COVID-19 Interferon-β Mortality SARS-CoV-2 Treatment Impact of early interferon-β treatment on the prognosis of patients with COVID-19 in the first wave: A post hoc analysis from a multicenter cohort